▎WuXiEdited by Kant Content Team
Reduce the Risk of Disease Progression or Death by 60%, Johnson & Johnson's Antibody Combination Therapy Receives FDA Approval
Johnson & Johnson announced the other day that the U.S. FDA has approvedDarzalex Faspro (daratumumab + hyaluronidase) in combination with bortezomib, lenalidomide, and dexamethasone forms a quadruplet therapy (D-VRd) for the treatment of newly diagnosed multiple myeloma patients.This allows patients to receive this Darzalex Faspro-based quadruple therapy at the time of initial diagnosis, significantly improving treatment outcomes.
This approval is based on data from the Phase 3 clinical trial PERSEUS, which showed that D-VRd significantly improved the primary endpoint of progression-free survival (PFS) compared to the active control group.Compared with the triple therapy of bortezomib, lenalidomide, and dexamethasone (VRd), D-VRd reduced the risk of disease progression or death by 60% (HR=0.40, 95% CI: 0.29, 0.57, p<0.0001).D-VRd Induction and Consolidation Therapy Achieves Deeper Remission at the End of the Consolidation Phase Compared to VRd: Minimal Residual Disease (MRD) Negative Rate of 57.5% vs. 32.5%.Darzalex Faspro, jointly developed by Johnson & Johnson and Genmab, isThe first anti-CD38 antibody that can be administered via subcutaneous injection, reducing the time patients spend receiving treatment from several hours to just a few minutes.
$60 Million Boosts Potential "Best-in-Class" RNA Editing Therapy Development
AIRNA Announces Successful Completion of Oversubscribed $60 Million Financing, Bringing Series A Total to $90 Million. The proceeds will be used to advance the company's lead candidate into clinical trials and further develop AIRNA's broad pipeline.
AIRNA was founded with the support of ARCH Venture Partners and is committed to building on the work of co-academic founder Thorsten Stafforst.Ph.D.Pioneering research published with Dr. Jin Billy Li, creating a new generation of RNA therapies. AIRNA develops drugs through its RESTORE+ platform, which optimizes oligonucleotide sequences, chemistry, and delivery to achieve precise, efficient, and safe RNA editing.AIRNA's first candidate drug is a potential "best-in-class" treatment for Alpha-1 Antitrypsin Deficiency (AATD)., a hereditary condition associated with severe lung and liver diseases.
▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long press and scan the QR code above to access "WuXi AppTec Live Studio" and watch live discussions and exciting replays on related topics.
[1] DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based quadruplet regimen approved in the U.S. for patients with newly diagnosed multiple myeloma who are transplant-eligible. Retrieved July 31, 2024, from https://www.prnewswire.com/news-releases/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-quadruplet-regimen-approved-in-the-us-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-eligible-302210443.html[2] AIRNA Raises Oversubscribed $60 Million Financing to Advance New Class of RNA Editing Medicines and Progress Best-in-Class AATD Program into the Clinic. Retrieved July 31, 2024, from https://airna.com/airna-raises-oversubscribed-60-million-financing-to-advance-new-class-of-rna-editing-medicines-and-progress-best-in-class-aatd-program-into-the-clinic/Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is intended solely for the purpose of information exchange, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain reprint guidelines.
Share，PointLike，In ViewFocusing on Global Biomedical Health Innovation
